<DOC>
	<DOCNO>NCT00323869</DOCNO>
	<brief_summary>A multi-center study bevacizumab combination gemcitabine carboplatin treatment newly-diagnosed advanced non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Phase II Bevacizumab , Gemcitabine Carboplatin Newly Diagnosed Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This open-label , phase 2 , single-arm , multi-center study bevacizumab combine gemcitabine carboplatin . This treatment newly-diagnosed advanced non-small cell lung cancer ( NSCLC ) , exclude squamous cell carcinoma . All subject receive 15 mg/kg bevacizumab every 3 week cycle , 1000 mg/m² gemcitabine day 1 8 every 3 week cycle carboplatin ( AUC= 5 ) every 3 week . Carboplasm administer 1 hour prior gemcitabine infusion , bevacizumab administer 1 hour follow chemotherapy infusion . Subjects receive maximum 6 cycle chemotherapy , treatment bevacizumab may continue long patient evidence progressive disease significant treatment-related toxicity .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion Criteria : Age 18 high Life expectancy least 3 month ECOG Performance status 0 1 Advanced stage nonsmall cell lung cancer , NSCLC , Stage IIIB malignant pleural effusion Stage 4 , exclude squamous cell histology , measurable evaluable disease No prior systemic therapy advance NSCLC ( prior therapy early stage disease one regimen acceptable complete least 6 month prior study entry ) Palliative radiotherapy painful bony metastasis permit prior study entry complete prior initiation study treatment , residual sequela therapy bone marrow suppression Willingness use appropriate contraception avoid pregnancy study Leukocytes ≥ 3,000/µL Absolute neutrophil count ≥ 1,500/ µL Platelets ≥ 100,000/ µL Total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 x institutional upper limit normal Creatinine : Within normal institutional limit Creatinine clearance ≥ 60 mL/min/1.73 m² patient creatinine level institutional normal Ability sign inform consent Prior systemic treatment advance NSCLC ( one prior regimen 4 cycle neoadjuvant adjuvant therapy early stage disease allow , complete least 6 month prior study entry ) Known brain metastasis Prior treatment bevacizumab History allergic reaction Sensitivity attribute compound similar chemical biologic composition bevacizumab Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Concomitant chemotherapy , radiotherapy , investigational agent Evidence bleed diathesis Coagulopathy Use anticoagulant agent include warfarin , heparin , aspirin , NSAIDs Pregnant Lactating Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study Minor surgical procedure within 7 day prior day 0 Fine needle aspiration within 7 day prior day 0 Core biopsy within 7 day prior day 0 Urine protein : creatinine ratio ≥ 1.0 screen History abdominal fistula within 6 month prior Day 0 Gastrointestinal perforation within 6 month prior Day 0 Intraabdominal abscess within 6 month prior Day 0 Serious , nonhealing wound Ulcer Bone fracture Lung carcinoma squamous cell histology Any histology close proximity major vessel Significant cavitation assess treat investigator consultation attend radiologist History hemoptysis ( bright red blood 1/2 teaspoon ) Blood pressure &gt; 150/100 mmHg Unstable angina New York Heart Association ( NYHA ) Grade 2 great congestive heart failure History myocardial infarction within 6 month History stroke within 6 month Clinically significant peripheral vascular disease Psychiatric illness/social situation would limit compliance study requirement Another active malignancy except nonmelanoma skin cancer Inability comply study and/or followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>